August 11, 2023
Elite Diagnostic Limited (ELITE) for the year ended June 30, 2023, reported a 21% increase in Income totaling $755.37 million compared to $624.22 million in the corresponding period last year. Income for the fourth quarter had an 8% increase to close at $189.61 million compared to $175.69 million for the comparable quarter of 2022.
Direct Costs amounted to $228.07 million (2022: $191.96 million), this represents an increase of 19% year over year. Consequently, Gross Profit increased by 22% to $527.31 million compared to $432.26 million for the year ended June 30, 2022. The company booked Gross Profit of $136.74 million for the fourth quarter versus $124.13 million reported for the similar quarter of 2022.
Elite’s Administrative Expenses increase by 34% to close at $324.21 million (2022: $242.29 million), while Depreciation & Amortization increased by 38% from $107.53 million in 2022 to $148.75 million in the period under review. As a result, Operating Profit for the year ended June 30, 2023, amounted to $54.35 million, a 34% decrease relative to $82.45 million reported in 2022.
Foreign Exchange Loss for the year ended June 30, 2023, amounted to $4.56 million, a 30% decline relative to $6.47 million reported in 2022. Finance Cost totalled $46.98 million a 72% increase from the corresponding period last year. (2022: $27.32 million).
Profit Before Tax for the year ended June 30, 2023, amounted to $2.82 million, a 94% reduction relative to $48.66 million reported in 2022. Loss Before Tax for the fourth quarter amounted to $1.74 million (2022: Profit before tax of $13.92 million).
There was no Income Taxation for the period therefore, Net Profit for the year ended amounted to $2.82 million, a 94% decrease from the $48.66 million reported in 2022. For the fourth quarter, Net Loss was $1.74 million (2022: Net profit of $13.92 million).
Consequently, Earnings Per Share for the year ended amounted to $0.008 (2022: EPS: $0.138), while Loss Per Share for the quarter totaled $0.005 (2022: EPS: $0.04). The twelve-month trailing EPS was $0.008, and the number of shares used in these calculations was 353,400,000.
Notably, ELITE’s stock price closed the trading period on August 11, 2023, at a price of $2.11 with a corresponding P/E ratio of 264.86x.
Balance Sheet Highlights
The company’s assets totalled $1.09 billion (2022: $919.56 million). Notably, Right of use asset rose to $108.09 million (2022: $24.46 million), while Receivables recorded a 102% increase to $119.47 million (2022: $59.26 million).
Shareholder’s equity was $474.29 million (2022: $478.54 million), representing a book value per share of $1.34 (2022: $1.35).
Disclaimer:
Analyst Certification -The views expressed in this research report accurately reflect the personal views of Mayberry Investments Limited Research Department about those issuer (s) or securities as at the date of this report. Each research analyst (s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view (s) expressed by that research analyst in this research report.
Company Disclosure -The information contained herein has been obtained from sources believed to be reliable, however its accuracy and completeness cannot be guaranteed. You are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Mayberry may effect transactions or have positions in securities mentioned herein. In addition, employees of Mayberry may have positions and effect transactions in the securities mentioned herein.
